Hudson M A, Catalona W J
Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri 63110.
J Urol. 1990 Jun;143(6):1174-7. doi: 10.1016/s0022-5347(17)40218-7.
A total of 21 patients received adjuvant radiation therapy after radical prostatectomy for a persistently detectable prostate specific antigen value (more than 0.6 ng. per ml.) postoperatively. Adjuvant radiation therapy decreased serum prostate specific antigen values to the undetectable range in 6 of 21 patients (29%) all of whom have remained free of tumor recurrence with a mean followup of 12.6 months (range 6 to 30). Three patients initially showed a decrease in serum prostate specific antigen to undetectable levels but they subsequently demonstrated an increasing level within 12 months after adjuvant radiation therapy. Additionally, 7 of 13 patients whose prostate specific antigen values remained in the detectable range despite adjuvant radiation therapy have had clinical evidence of tumor recurrence. Further followup will be required to determine what ultimate impact adjuvant radiation therapy will have on survival free of tumor.
共有21例患者在前列腺癌根治术后因术后前列腺特异性抗原值持续可检测到（超过0.6纳克/毫升）而接受辅助放疗。辅助放疗使21例患者中的6例（29%）血清前列腺特异性抗原值降至检测不到的范围，所有这些患者均未出现肿瘤复发，平均随访12.6个月（范围6至30个月）。3例患者最初血清前列腺特异性抗原降至检测不到的水平，但随后在辅助放疗后12个月内显示该水平升高。此外，13例患者尽管接受了辅助放疗，但其前列腺特异性抗原值仍处于可检测范围内，其中7例有肿瘤复发的临床证据。需要进一步随访以确定辅助放疗对无瘤生存的最终影响。
